Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

APRIL:TACI axis is dispensable for the immune response to rabies vaccination.

Haley SL, Tzvetkov EP, Lytle AG, Alugupalli KR, Plummer JR, McGettigan JP.

Antiviral Res. 2017 Aug;144:130-137. doi: 10.1016/j.antiviral.2017.06.004. Epub 2017 Jun 12.

2.

Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Haley SL, Tzvetkov EP, Meuwissen S, Plummer JR, McGettigan JP.

J Virol. 2017 Mar 29;91(8). pii: e02435-16. doi: 10.1128/JVI.02435-16. Print 2017 Apr 15.

3.

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Dunkel A, Shen S, LaBranche CC, Montefiori D, McGettigan JP.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1126-38. doi: 10.1089/AID.2014.0319. Epub 2015 May 5.

4.

Lymph node but not intradermal injection site macrophages are critical for germinal center formation and antibody responses to rabies vaccination.

Lytle AG, Shen S, McGettigan JP.

J Virol. 2015 Mar;89(5):2842-8. doi: 10.1128/JVI.03409-14. Epub 2014 Dec 24.

5.

Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs.

McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ.

Vaccine. 2014 Mar 26;32(15):1716-9. doi: 10.1016/j.vaccine.2014.01.043. Epub 2014 Feb 7.

6.

ICAM-1-based rabies virus vaccine shows increased infection and activation of primary murine B cells in vitro and enhanced antibody titers in-vivo.

Norton JE Jr, Lytle AG, Shen S, Tzvetkov EP, Dorfmeier CL, McGettigan JP.

PLoS One. 2014 Jan 29;9(1):e87098. doi: 10.1371/journal.pone.0087098. eCollection 2014.

7.

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.

Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ.

PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.

8.

Reinvestigating the role of IgM in rabies virus postexposure vaccination.

Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP.

J Virol. 2013 Aug;87(16):9217-22. doi: 10.1128/JVI.00995-13. Epub 2013 Jun 12.

9.

B cell infection and activation by rabies virus-based vaccines.

Lytle AG, Norton JE Jr, Dorfmeier CL, Shen S, McGettigan JP.

J Virol. 2013 Aug;87(16):9097-110. doi: 10.1128/JVI.00800-13. Epub 2013 Jun 12.

10.

Investigating the role for IL-21 in rabies virus vaccine-induced immunity.

Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP.

PLoS Negl Trop Dis. 2013;7(3):e2129. doi: 10.1371/journal.pntd.0002129. Epub 2013 Mar 14.

11.

Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection.

Dorfmeier CL, Lytle AG, Dunkel AL, Gatt A, McGettigan JP.

J Virol. 2012 Nov;86(21):11533-40. doi: 10.1128/JVI.00615-12. Epub 2012 Aug 15.

12.

Experimental rabies vaccines for humans.

McGettigan JP.

Expert Rev Vaccines. 2010 Oct;9(10):1177-86. doi: 10.1586/erv.10.105. Review.

13.

Characterization of a single-cycle rabies virus-based vaccine vector.

Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ.

J Virol. 2010 Mar;84(6):2820-31. doi: 10.1128/JVI.01870-09. Epub 2010 Jan 6.

14.

The cell biology of rabies virus: using stealth to reach the brain.

Schnell MJ, McGettigan JP, Wirblich C, Papaneri A.

Nat Rev Microbiol. 2010 Jan;8(1):51-61. doi: 10.1038/nrmicro2260. Review.

PMID:
19946287
15.

Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.

Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ.

Vaccine. 2009 Dec 11;28(2):299-308. doi: 10.1016/j.vaccine.2009.10.051. Epub 2009 Oct 29.

16.

Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.

Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP.

J Infect Dis. 2009 Oct 15;200(8):1251-60. doi: 10.1086/605949.

17.

Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.

Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ.

Virology. 2008 Dec 20;382(2):226-38. doi: 10.1016/j.virol.2008.09.019. Epub 2008 Oct 21.

18.

Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.

Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP.

Vaccine. 2008 Nov 25;26(50):6405-14. doi: 10.1016/j.vaccine.2008.08.069. Epub 2008 Sep 18.

19.
20.

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.

J Infect Dis. 2007 Apr 1;195(7):980-8. Epub 2007 Feb 20.

PMID:
17330788
21.

A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.

Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B.

Virology. 2006 Dec 5-20;356(1-2):147-54. Epub 2006 Aug 30.

22.

Rabies virus glycoprotein as a carrier for anthrax protective antigen.

Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ.

Virology. 2006 Sep 30;353(2):344-56. Epub 2006 Jul 3.

23.

siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects.

Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ.

Virology. 2006 May 10;348(2):489-97. Epub 2006 Feb 9.

24.

Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ.

Virology. 2006 Jan 20;344(2):363-77. Epub 2005 Oct 14.

25.

Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.

Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ.

Virology. 2005 Jan 5;331(1):82-93.

26.

Rabies virus nucleoprotein as a carrier for foreign antigens.

Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9405-10. Epub 2004 Jun 14.

27.

Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.

McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ.

Curr HIV Res. 2003 Apr;1(2):229-37. Review.

PMID:
15043205
28.

Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A.

Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN.

J Virol. 2004 Mar;78(6):2657-65. Erratum in: J Virol. 2004 May;78(10):5532.

29.
30.
31.

Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.

McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ.

J Virol. 2003 Jan;77(1):237-44.

32.

HIV-1 vaccines: the search continues.

McGettigan JP, McKenna PM, Schnell MJ.

Clin Lab Med. 2002 Sep;22(3):799-820, viii. Review.

PMID:
12244598
33.

Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.

Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B.

J Virol. 2002 Apr;76(7):3374-81.

34.

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.

Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ.

Virology. 2002 Jan 5;292(1):24-34.

35.

Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ.

J Virol. 2001 Nov;75(22):10623-9.

36.
37.

Genetic engineering of live rabies vaccines.

Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ.

Vaccine. 2001 May 14;19(25-26):3543-51.

PMID:
11348722
38.

High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector.

Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B.

J Immunol Methods. 2001 Jun 1;252(1-2):199-206.

PMID:
11334980
40.

A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.

Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14680-5.

41.

Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach.

Morimoto K, Foley HD, McGettigan JP, Schnell MJ, Dietzschold B.

J Neurovirol. 2000 Oct;6(5):373-81.

PMID:
11031690
42.

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3544-9.

Supplemental Content

Loading ...
Support Center